title: [Ways of improving adherence on telaprevir-based therapy in patients with chronic HCV infection].
abstract: OBJECTIVE
  To present the ways of improving adherence on telaprevir-based therapy in patients with chronic HCV infection.
  
  
  BACKGROUND
  Telaprevir is a direct antiviral agent, registered in Russian Federation as a treatment for chronic hepatitis C genotype 1 patients in combination with pegylated interferon and ribavirin (PR). Phase III clinical trials showed a significant improvement in efficacy when adding telaprevir to pegylated interferon and ribavirin compare to the duel PR treatment along. Standard telaprevir regiment 750 mg 3 times per day is associated with difficulties in keeping adherence to the treatment. Here we present the results of administering telaprevir 1125 mg twice daily.
  
  
  CONCLUSIONS
  Telaprevir-based 1125 mg twice daily regimen in combination with PR is comparable with telaprevir 750 mg every 8 hours treatment if looking at rates of SVR, relapse incidence, viralogical insufficiency, pharmacokinetics, safety, also taking in consideration higher treatment adherence even in HCV cirrhotic patients.
authors.forename: É Z
authors.initials: ÉZ
authors.lastname: Burnevich
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Tikhonova
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage; D008297:Male; D055118:Medication Adherence; D009842:Oligopeptides / Q000008:administration & dosage*; D012254:Ribavirin / Q000008:administration & dosage
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D012254:Ribavirin; C486464:telaprevir; D007372:Interferons